Good morning.
Macro just gave us a clean tape. Trump pulls the strike on Iran, oil gets ripped -6%, yields fall off the nosebleed — S&P gaps up +1% and every duration asset breathes. This is a textbook macro-driven relief rally. But the real story this week isn't the gap-up; it's whether the AI capex validation loop holds. Tonight, AMZN and MSFT delivered. AMZN JUST BROKE $3T. AWS printed 36.7% growth — FASTEST IN 18 QUARTERS, fifth straight acceleration — and they raised capex specifically because memory costs are biting. MSFT disclosed 30M+ PAID M365 COPILOT SEATS, roughly 10M net adds in one quarter, double the prior pace. That's ROI re-rating fuel, not narrative.
Futures hold the gains. ES and NQ both +0.5% pre-market — no fade yet. The movers are all in the AI complex: MU ripping on memory tightness, AVGO strong on optical, NOW and DDOG getting hit on multiple compression fears. AAPL grinding lower despite the tax — still digesting last week's guide-down. CAT down ahead of tomorrow's print; the "AI-driven manufacturing renaissance" thesis needs hard confirmation. JNJ and DKS look horrid. Everything else is riding the beta wave.
Asia closed constructive. ISM Manufacturing hit 55.6 — STRONGEST SINCE MAY 2022 — and MarketWatch pinned it directly on the AI boom's supply chain pull. That's AI capex leaking into macro hard data. Meanwhile, the US/Japan coordinated yen intervention ($36.6B, first joint action in 15 years) is tightening one funding channel for leveraged AI longs. The setup is risk-on, but Friday's NFP is the landmine. Warsh's hawkish shadow hasn't lifted.
Three themes frame today:
1. The demand signal chain just got tighter. TrendForce up-revised 2026 AI server shipments to +31% YoY. Taiwan supply chain mid-caps are printing record revenues — 牧德 +31.8% YoY, 中華精測 +49.9% — all attributed to AI test demand. ISM shows supply shortages accelerating. This is no longer narrative; it's order books.
2. China is structural undercut on cost, not just closing the capability gap. Alibaba dropped Qwen3.8-Max (2.4T params). DeepSeek V4-Flash costs 3 cents per inference vs Anthropic's $3.15 — THAT'S A 100x COST ADVANTAGE. Markets haven't priced the threat to hyperscaler inference pricing power. If enterprise self-deployment of open-weight models rises materially, the cloud revenue acceleration story gets re-underwritten.
3. Memory is now a prime input — and a macro factor. AWS explicitly raised capex to cover memory costs. Kioxia guiding +30% ASPs. LTAs are locking 3-5 year supply. This isn't a cyclical blip; it's a structural repricing of the stack. MU, SNDK, and WDC have the leverage here. CXMT's capacity expansion is real, but Entity List risk keeps Western suppliers structurally insulated.
4. AI safety is becoming a compliance tax. EU AI Act enforcement activated today. OpenA and Anthropic are in scope — up to 3% of turnover in fines. Agent escape events last week turned this from left-tail narrative to real constraint. Watch cybersecurity names as non-obvious beneficiaries — Visa's $2.4B BioCatch acquisition is one signal.
We'll hit up AMZN, MSFT, and MU first, then get to semis/optical — AVGO, NVDA, COHR, LITE — to see if the infrastructure complex can hold the bid.
Eight PT raises, one methodology trim, zero downgrades. AMZN's Q2 print did what earnings are supposed to do — reset the narrative. AWS AT 37% GROWTH with 840bps of QoQ acceleration makes everything else background noise. The street threw PTs at the tape from $310 to $400, median $350. The only "cut" (Cantor, $330→$320) came with raised estimates and a lower multiple — valuation discipline, not thesis damage. No neutrals on this name.
Consolidated bull case: AWS is re-accelerating into an enterprise AI adoption wave, AI ARR hit a $25B run rate, backlog sits at $496B, and the margin math finally works in the shareholder's favor. Benchmark's Kurnos — nearly two decades covering the name — calls the print "among the most impressive in at least the last 10 years." JPMorgan goes bigger on the top line: 20% total revenue growth, FASTEST IN 20 QUARTERS, with Stores and Ads contributing alongside AWS.
The PT cluster shows where conviction sits: TD Cowen, Truist, KeyBanc all at $350. JPMorgan at $365. Benchmark as the bull-case outlier at $400 — that's the must-own-with-duration camp, explicitly acknowledging expectations may run ahead. The low end (UBS $318, Cantor $320, RBC $330) isn't bearish — same thesis, just multiple-cautious on entry.
What actually changed:
Bull: AWS re-acceleration is the whole ballgame. 37% growth, $25B AI ARR, $496B backlog — the momentum compounds. Benchmark says Jassy outlined the 10-year investment case "more completely than other hyperscalers" and at 10x 2027 OIBDA, the stock hasn't finished repricing. UBS projects ~39% AWS growth in H2 2026 and 40%+ next year with the Trainium catalyst — and the margin math does the heavy lifting: AWS revenue dollar growth into 2027 makes expansion almost unavoidable unless SG&A grows at three times the recent pace.
"Amazon would need to increase SG&A expenses at three times the recent pace to prevent margin expansion given AWS revenue dollar growth into 2027." — UBS
Bear: Blemishes exist. Q3 revenue guide slightly below consensus — first crack in the acceleration story. Negative FCF persists, and Benchmark itself flags "unanswered funding questions" around $220B of capex. UBS concedes investors won't model stable-to-rising AWS margins with AI compute mix climbing. Cantor trimming its multiple to 30x while raising estimates is the classic great-company, full-price signal — worth watching if the stock grinds toward that $278 high.
"AWS acceleration has significant runway ahead as enterprise adoption of AI accelerates in coming quarters." — Cantor Fitzgerald (still a top pick at the reduced multiple)
AMZN just gave PMs permission to keep playing the AI capex trade. $25B AI ARR and a $496B backlog at one hyperscaler means enterprise AI spend is booked, not hypothetical. That lifts the whole cloud complex — MSFT and GOOGL face a higher bar on their next prints, but the re-acceleration narrative benefits all three. The OpenAI-on-Trainium news is a direct shot across NVIDIA's bow; watch the custom silicon names. And $220B of capex extends the power/gen infrastructure supercycle — this is a read-through to the whole electrical equipment, data center, and utility complex. r/r on AMZN itself is fine but not screaming; the real alpha may be in the suppliers.
PWR IS THE AI POWER TRADE IN ITS PUREST FORM — AND THE MARKET IS PRICING IT THAT WAY. +58% YTD, +17% THE DAY OF THE PRINT, $100B MARKET CAP. The narrative's intact, the backlog's real, and the sell-side can't agree on the endgame: Truist says $976, Mizuho says $741. Direction's clear. Magnitude isn't.
Q2 beat on every line. Adjusted EPS $4.24 vs ~$3.29 consensus, +29%. Revenue $9.56B, 11% over. EBITDA cleared by 16-22% depending on the bogey. Management raised FY26 EPS to $16.45-$16.95 (midpoint $16.70, +55% YoY) and EBITDA $600M to $4.09-4.21B.
The quality read: Mizuho breaks the $4.55B revenue-guide increase into ~29% M&A and 71% organic outperformance plus visibility. THAT'S THE DETAIL THAT MATTERS. This isn't a growth-by-acquisition story — the core is firing faster than anyone modeled.
Segment highlights:
Management didn't just tweak the guide — they doubled the growth algorithm. Electric Grid & Gas Utility: +20-25% (from 10-20%). Technology & Load Centers: +220-240% (from 100-120%), acquisitions included. That second one is AI/data center load growth hitting the P&L at an accelerating clip. Mizuho's out-year EBITDA ladder — $4.1B → $4.9B → $5.6B — says the deceleration is slow. This isn't a one-year trade.
TD Cowen $785 Buy. Bernstein $748 Market Perform. Mizuho $741 Neutral. Then Truist at $976 Buy (raised from $940) — nearly $200 above the next closest bull. Either Truist saw the re-rating first or they're planted at the high end. Mizuho's Neutral is the honest counterweight: valuation already reflects the stronger outlook. Translation — the good news is in the price.
The bull fuel:
"The backlog has yet to include NiSource or meaningful 765kV transmission projects."
Record backlog and the two biggest visible catalysts aren't even booked yet. That's a forward curve story, not a trailing print story.
Bull: Multi-year electrification supercycle with self-reinforcing acceleration. AI load forces utility capex, which feeds the backlog, which feeds the guide. 40x for 55% EPS growth works if the duration runs longer than the multiple implies.
Bear: The market pays up for perfection. 40x forward, +58% YTD, +69% over the past year — the crowd is already here. Margin quality is partly M&A mix, especially in Underground. If anything slips on the 220% Tech & Load Centers guide, the multiple gives you zero downside cushion.
Stop fighting the liquid cooling tape. NVT remains the cleanest way to play the AI infrastructure buildout that doesn't require you to own a megacap. Another blockbuster quarter, two broker PT raises on the same day, and management leaning IN — building capacity before the orders even book.
Q2 was absurd. Organic growth +47%, 22 POINTS ahead of consensus. Adjusted EPS $1.45 vs $1.16 bogey. Revenue $1.5B vs $1.26B expected. That's a 53% total sales bump, and the $2.5B backlog is converting cleanly.
Management didn't just beat — they swung. FY26 organic guidance raised 11 points at the midpoint to 32-34%. EPS guide up to $5.00-$5.10. The kicker: FY26 data center sales now expected to exceed $2B, MORE THAN DOUBLE THE 2025 FIGURE.
Third liquid cooling facility announced in Blaine, Minnesota. The first Blaine plant is already running ahead of plan. This is a company that sees the demand curve and is putting steel in the ground to meet it.
Also worth a hat tip: pricing and productivity offset $50M+ in tariff and inflation costs. Operating income +61% to $323M. ROS 21.9%, up 110bps. This isn't just a growth story — they're protecting margins while scaling.
Evercore ISI to $210, Outperform. UBS to $225 from $200, Buy. No downgrades, no trim-thesis hedging. Evercore lifted estimates 8-16% post-print. UBS went bolder — 2027 sales and EPS now 17-19% above consensus with 25% organic growth projected vs 16% consensus. UBS sees 2027 EPS of $6.91 vs $5.82 consensus. That's 30% earnings growth on top of 55% expected THIS year.
The strongest line comes from Evercore, and it captures the entire bull thesis:
"The company is committing capacity ahead of its order book."
That's conviction. They're not waiting for confirmation — they're building for a pipeline they trust.
Bull case: The liquid cooling cycle stretches for years, not quarters. Backlog visibility at $2.5B plus capacity added ahead of the curve means UBS's $6.91 could still be low. This is a company operating from a position of backlog, not hope. Rate of change is violently positive — guidance up 11 points in one shot.
Bear case: The stock isn't cheap. 43x P/E, and third-party fair value screens are already flashing overvalued. Up 72% in a year, the positioning is crowded and the setup is rich. One bad AI capex datapoint from a hyperscaler and a stock priced for perfection gets hit hard. Also — 47% organic growth compares get brutal into next year, even if absolute demand stays strong.
Stock at $161 (call it a $26B market cap), up 52% YTD. Two analysts in the 210-225 zone and both moving UP, not converging on a staid bogey. The tape says momentum is the dominant factor, but the fundamentals support it. Until 2027 estimates start rolling over — and they're still going the other direction — the path of least resistance is higher. Keep an eye on any hyperscaler capex commentary; that's the outside risk to this name.
THE STREET ISN'T JUST SPLIT ON CLOUDFLARE — IT'S IN TWO DIFFERENT TIME ZONES. Guggenheim sits at Sell/$140. Citizens just went to $330. That's a $190 spread on a stock at $283.54. Earnings Thursday. This one has real downside torque.
NET trades 3.5% off its 52-week high ($293.80) and up 41.5% YTD. The problem: at 34.5x EV/NTM revenue, it's the most expensive name in Guggenheim's coverage — full stop. P/B at 64.9x. The multiple bakes in flawless execution.
Revenue should beat Thursday. Guggenheim models ~180bps of upside to Street consensus — but that's the deceleration tell. The last three quarters delivered 300-410bps of beat. The rate of change is going the wrong way, and Cantor (Neutral, PT to $250 from $230) flags the same bogeys: gross margin trajectory, growth deceleration, DBNRR stabilization, restructuring execution. Not exactly an "all clear" list into the print.
The bull camp is loud and getting louder. Truist to $300 (from $250), Citizens to $330, TD Cowen to $300 (from $265). Collective thesis: platform consolidation, AI expansion, and the OpenAI partnership on AI search indexing give NET a narrative hook competitors can't touch. They see a ~30% grower that turns profitable this year — consensus EPS at $1.27. Channel revenue hit 30% of mix for the first time in Q1. Field checks positive: three of four partners above plan.
The bear camp isn't blinking. Guggenheim's Sell/$140 implies 50% downside. Their logic is simple: at 34.5x forward revenue, you need the growth narrative pristine. It's not. The beat is shrinking, DBNRR is declining sequentially, and restructuring/layoffs are in the headlines.
The sharpest line out of Guggenheim has nothing to do with the multiple. President of Revenue Mark Anderson retires at year-end — the guy who took the go-to-market motion from startup chaos to enterprise grade. Losing him mid-restructuring cycle is the kind of thing that doesn't hit the model until two quarters later, when a number comes up short.
"Guggenheim views the departure as a material and underappreciated risk, noting Anderson was key to lifting the company's go-to-market motion into enterprise grade."
Bull: Platform attach + AI narrative + 30% growth at scale justifies the premium. The $300-330 cluster says the growth crowd still believes the story compounds.
Bear: 34.5x revenue for a company with shrinking beats, falling retention, and its top sales exec walking out the door is horrid r/r. Options market implies an 11% move post-earnings — and this stock has only exceeded expectations twice in the last eight prints.
NET is a 30% grower at a 34.5x multiple with decelerating beats and a sales chief in the exit door. The long side needs Thursday to be perfect. The short side just needs it to be good, not great. With the option-implied move at 11% off a $283 base, the asymmetry into the print favors the bears — even if the fundamental story stays intact.
Apple's the AI-unwind port in the storm — UP 15% IN JULY while SMH dumped ~18% and the S&P fell 1% — but at 36.7x earnings with a 71% NTM P/E PREMIUM TO THE S&P, the Street's split on whether the iPhone 17/18 cycle pays for the multiple. TD Cowen says yes, going to $400 (Street high). UBS says no, Neutral at $296. Same tape, two conclusions. Seven analysts, targets from $250 to $400 — nobody's indifferent.
FQ3 REVENUE $109.4B (a hair under consensus), EPS $2.02 vs $1.95 expected. Problem is the guide: FQ4 REVENUE GROWTH 9-11% Y/Y, below the ~12% consensus. iPhone/Mac beat, iPad missed. Services growth decelerating — Morgan Stanley trimmed PT to $360 on exactly that. Rosenblatt raised to $300 citing "exceptional" iPhone sales. Goldman cut to $360, still Buy, on weak guidance. Oppenheimer just shrugs: Perform.
TD Cowen's $400 target is the bull playbook: products getting more expensive (iPad/Mac price hikes already in, iPhone next), 2nm chip cadence, and the iPhone 17 cycle extending into the 18 on AI Siri + the Upgrade program. Then the Services kicker that answers the deceleration worry:
"A possible iCloud+ plan that includes AI cloud compute as a potential new growth driver for Apple's Services segment."
That's the clean AI monetization path — Apple gets a Services re-rate without the capex bleed that hits Meta/GOOGL. Cash flow stays the cleanest in Mag 7.
UBS isn't moved. Neutral at $296. Tougher iPhone comps, modest Services, gross margin pressure into FY27. The valuation line is brutal: premium to S&P widened to ~71% from ~50% at end of June while FY27/28 estimates barely budged. KeyBanc's at $250, calling Q3 mixed and the valuation full. The bear case isn't broken Apple — it's a multiple that ran ahead of the fundamentals, and an AI strategy that's still more promise than product.
Rate of change cuts both ways: iPhone 17/18 acceleration is real, but so is the Services slowdown and margin compression into tougher comps. Nobody debates Apple's status as the market's favorite AI capex-avoidance trade. The fight is whether that's a September gift or a trap at 36.7x. TD Cowen's buying the gift. UBS thinks it's wrapped.
Evercore just admitted they were wrong for 18 months. That's the signal. Downgraded back in November 2024, sat through the margin bleed, now flips to Outperform with a $502 PT (from $453). Bernstein's been at Outperform with $534 all along. Convergence: margin recovery is real, backlog is loaded, and data center electrification remains the strongest structural narrative in industrials.
The original sin was self-inflicted. ETN fell behind on inflation while standing up massive new capacity for the data center supercycle. Too much plant, too little pricing. That now reverses.
"The company had fallen behind on inflation and faced inefficiencies from adding significant new capacity, but has now addressed both issues through pricing actions and completing 18 of 24 factory capacity additions."
That's the Evercore upgrade thesis. The timing matters: Q1 and Q2 2026 were the bottom of YoY EPS growth. Margin expansion returns by Q4 2026, with easy comps running through summer 2027. That's a multi-quarter runway of positive rate-of-change — and this market pays up for rate-of-change.
Beat and raise. Q2 revenue $8.5B vs $8.16B consensus. Segment profit $1.97B, +7% vs estimates. EPS beat by 3%. The guide: FY26 EPS up 2% to $13.50, organic growth +200bps. Backlog is the kicker — worldwide Electrical backlog equal to 76% of the 2026 Electrical sales guide. The Mobility spin-off in early 2027 cleans up the growth profile.
Stock at $431, near the $436.74 52-week high, +31% YTD. The market sees the inflection — it's not hiding.
Bernstein's angle: 800VDC. ETN goes grid-to-chip — solid-state transformers, DC breaker tech, power electronics, plus cooling (cold plates, CDUs). The Resilient and Boyd acquisitions fill the holes. This isn't a transformer company anymore. It's a full-stack electrification play on the densest compute build-out in history. That's what gets PMs to look through a 42x multiple.
Bull: margin expansion returns in two quarters with easy comps through summer 2027, backlog at 76% of sales guides, Mobility spin-off raises the standalone growth profile, and 800VDC positioning compounds every quarter.
Bear: 42x earnings for a company that just printed trough margins. Evercore was the last bear — the upgrade makes the bull case consensus. The spin-off is a subtraction, not a growth driver. You're paying for perfection at the exact moment everyone's talking about it.
I want to own the margin inflection. Just not at $431 with the upgrade in the rearview. The r/r is better on a pullback toward $400-410 than it is chasing the 52-week high. If it doesn't come, fine — the easy comps don't start until Q4 anyway. Patience beats cleverness here.
ThinkEquity goes ballistic — PT to $900 from $60 (yes, from $60). That's not a typo. Stock already at $823, up 686% in a year, and they say it's still undervalued. The call rests on HBM wafer intensity and take-or-pay supply-chain deals keeping DRAM earnings above normalized levels through FY27. HBM eats 3x the wafers of equivalent DDR5 bits, so supply relief keeps getting pushed out. The real fight has shifted to qualified CY28 supply.
ThinkEquity slaps a 12.1x multiple on $74.5 of normalized EPS. They're NOT capitalizing that guided 86% gross margin, NOT counting refundable customer deposits, NOT assuming incremental buybacks. So $900 is arguably the conservative version of their own math. But the unresolved question: can supply-chain agreements and premium mix hold normalized gross margins near 63% once conventional output ramps across the US, Taiwan, Korea, and China?
"The investment debate has shifted from the current shortage to qualified calendar year 2028 supply."
Elsewhere — Moody's upgrades to Baa1 on take-or-pay contracts covering half or more of revenue. UBS raises PT on $400B+ FCF through 2028. Citi drops MU from its catalyst watch on mixed memory read-across. Wolfe flags tech investor jitters despite solid earnings elsewhere. Mixed tape, but the HBM supercycle narrative remains intact.
UBS just made the first big bear call of the cycle — down to Neutral from Buy, PT $305→$270. Stock's already -14% on the week, so this isn't breaking news, but it's confirmation the China auto narrative has flipped. Not sure anyone catches this knife yet.
The thesis is simple: NXP is the wrong horse for both the AI trade and the China auto recovery. 17% domestic China exposure, 55% auto. China passenger vehicle sales -23% wholesale / -20% retail YTD, yet NXP's China revenue ROSE 25% YoY in Q2'26. That divergence doesn't resolve gently — UBS sees an inventory correction building for 2027.
"UBS said it is increasingly cautious on China auto-exposed semiconductor companies as domestic vehicle demand has weakened materially since late 2025."
The AI side doesn't save it. NXP's guided AI infra revenue — >$500M in 2026 — is roughly 3% of total. Compare to >$1B at IFX, TXN, ADI, STM. Edge AI monetization just takes longer; the market has no patience for that in this tape.
Rest of the Street is split, not collapsing: BofA trimmed PT to $300, Stifel sits at Hold ($282), Bernstein at Market Perform ($290). Morgan Stanley's the lonely bull — Overweight, $338, still hammering auto content gains.
The bull case in one line: 19.6x P/E, 0.49 PEG, 18 upward revisions. Valuation does temper the downside — that's exactly why UBS says Neutral, not Sell. But nobody pays up for cheap semis with a 2027 inventory correction staring at them.
Truist's PT tweak ($1,215 → $1,220) is a rounding error. The real signal: management walked long-term targets UP 13 months after the last guide — a rate-of-change tell that matters more than any price target.
Stock's up 38% YTD, trades at $1,037. Truist maintains Buy after a virtual sit-down with CEO Fox-Martin and CFO Leonetti. The message was all about INFERENCE AI — not training. Those workloads are driving volume AND pricing, which means the recurring revenue story accelerates, not just backlog.
"Inference AI workloads will drive volume and pricing tailwinds that accelerate recurring revenue growth."
Q2 already previewed the setup: EPS $4.83 vs $4.67 est, revenue $2.62B vs $2.59B est (+16% YoY), EBITDA margin 53% (+300bps), 134 MW of xScale leases closed. Stifel, UBS, Cantor, and Scotiabank all raised PTs post-print — nobody's fighting this tape.
Bull case is straightforward: scale + ecosystem = preferred connectivity platform for enterprises and service providers. Balance sheet's the enabler — it funds accelerated investment while Truist models >10% AFFO/share CAGR through 2029. (For a REIT, that kind of compounding gets PMs to pay up.)
Cantor's the last bull through the door before Thursday's print — PT to $327 from $226 (+45%), Overweight, and the read-through is simple: AI-native observability is the real deal, not just a narrative. STOCK'S ALREADY UP +124% IN SIX MONTHS to $272.92 (2% off the 52-week high), so this isn't a new call — it's an acceleration call into earnings.
Cantor's checks show at-or-above-plan demand, AI workloads moving into production, and Bits AI adoption gaining traction. Backed by 80% gross margins and 30% revenue growth, they see a beat-and-raise setup with conservative 2026 guidance as the floor. Options market is pricing UP TO A 13% POST-PRINT MOVE — that's the real bogey, not the PT.
"Cantor Fitzgerald said it expects another beat-and-raise quarter given its view of a conservative second-half setup based on the current 2026 guidance framework."
The rest of the Street's already lined up behind the same thesis — BofA $305, Citi/Morgan Stanley $300, Benchmark tops at $330 — all Overweight/Buy, all citing AI-native customers and improving core enterprise demand. That's a crowded long into the number. Fundamental case is clean; positioning risk is the thing that keeps PMs up at night.
PRICING IS THE WHOLE STORY. EVERCORE SEES JUNE QUARTER BEATS ON BOTH LINES AND THE STOCK IS UP 613% IN A YEAR — THIS IS NO LONGER A TURNAROUND, IT'S A REPRICING OF THE ENTIRE HDD SUPPLY CURVE.
Evercore reiterated Outperform / $575 PT into the print. Street is at $3.7B revenue (+41.7% y/y) and $3.29 EPS, but the firm says realized pricing lands low-to-mid teens — tight nearline supply, cloud demand, and value-based LTA pricing all pushing above consensus. September quarter already modeling $4.0B / $3.77 EPS, so the setup is for guidance to clear that bar too.
The analyst crowd is essentially unanimous on the thesis. Rosenblatt went $900 on 25x FY28 EPS. Wells Fargo moved to $730 from $575 on raised estimates through 2028. Three different PT clusters — $575, $730, $900 — but ONE narrative: supply discipline + AI-driven cloud demand + mix shift to high-capacity drives = pricing power sustained for multiple quarters.
"Positioned to exceed expectations on both revenue and earnings per share for the June quarter, driven primarily by stronger-than-expected pricing."
What actually matters for the stock, though: fiscal 2027 framework. Consensus at $18.2B revenue / $18.40 EPS implies 41.6% growth — but the real focus is HAMR. Tech ramp targets H1 CY2027 for 44TB drives, and the 40TB ePMR/UltraSMR platform is qualifying with three customers TODAY, with volume production this quarter. That's the bridge quarter story: nearline pricing holds, HAMR visibility builds, guidance beats, and the multiple debate starts.
Risk is baked in via the six-bagger move. But nobody's pressing shorts into a supply-constrained market with three customers qualifying on the next-gen platform. This prints or it doesn't — and Evercore thinks it does.
STIFEL REITERATES BUY WITH $800 PT — EARNINGS IN TWO DAYS, AND THE BULL CASE ISN'T SUBTLE. Hyperscalers just cranked CY26 capex again (Alphabet +8.1%, Amazon +10.0% vs. prior guides) with all four saying demand exceeds available capacity. For a company where data center is ~45-50% of sales, that's the whole ballgame.
Analog upswing broadening too — TI, NXP, STM all confirm the cycle, with auto recovering faster than expected. That's supportive but modest for SITM (auto/industrial/aero-defense is only ~19% of rev). Stifel's looking for a Q2 beat ($145M/$1.92 est) and September guidance above $162.4M/$2.09. Beat-and-raise setup into the print, and the stock's already up 177% in a year at $535 — so the market is very much paying attention.
"All four major hyperscalers reported demand exceeding available capacity."
That's the whole thesis in one line. Timing business acquisition from Renesas closing in the background adds a little M&A spice, but this is a data center story first, second, and third.
Truist flips to Buy on the ~45% July drawdown — the entry point, not the story, changed. Stock flat since late March initiation DESPITE Truist's 2028 EPS estimates up 30% (consensus +21%) over that span. That's the disconnect, and the upgrade is just monetizing it.
Optical (~45% of sales) demand remains solid: AI/datacenter and FTTH deployments still prioritized. Photonics MAP adds a second growth vector through decade-end. Truist sees 30% EPS CAGR 2026-2029; new $175 PT = ~27% upside vs. 32x 2027 / 24x 2028.
UBS also trimmed PT to $196 (from $228) but kept Buy — more conservative on fiber scale-up and photonics timing, estimates still 4%/19% above consensus for 2027/2028. Q2 beat ($0.78 vs $0.75e) got a muted tape reaction on near-term optics, but the estimate revision trend says the Street keeps finding reasons to lift numbers. Long-term story intact; you're just getting paid to wait at these levels.
The bull case is simple. The entry point isn't. Freedom Capital starts ENTG at Buy with a $140 PT (18% upside off $119), while Mizuho already sits at $180 after bumping from $175. That $40 spread on a $119 stock is the debate: everyone agrees on the demand side, nobody agrees on where the tape lands in 12 months.
Thesis is clean: AI/datacenter demand, record WFE spending, and a generational fab buildout = more wafers, more filtration/purification content per wafer. ENTG is the toll booth. It's mid-execution on its largest-ever footprint expansion ($1B+), with a new management team whose mandate is to ramp qualifications, production and shipments without blowing up the balance sheet (current ratio 3.21 — liquidity's not the bogey). Mizuho's WFE outlook raise for 2026-27 is the real rate-of-change tell; that's what justifies the higher number.
"Entegris' top priority for the next few years will be to efficiently ramp up product qualifications, production and shipments at the multi-year buildout."
The risk isn't demand — it's delivery. The market already paid for the +58% Y/Y run, so the stock needs execution plus continued WFE upside from here. Freedom's $140 is the "match the tape" target; Mizuho's $180 is the conviction call. Small noise: $0.10/qtr dividend (payable Aug 19), Materials Solutions president retires June 1 — Olivier Blachier takes over while keeping the strategy hat. Neither moves the stock.
Wells Fargo flips SEI to Overweight from Equal Weight and cuts the PT to $73 from $82 — don't misread the lower number. The stock's up 73% in a year. The call: behind-the-meter power with THREE HYPERSCALER CONTRACTS, 2.2+ GW disclosed, 3.2 GW planned capacity. Unit economics above 20% returns.
Trades in line with its power generating asset value, suggesting limited downside for a business with three hyperscaler customers and returns exceeding 20%.
That's the whole ballgame. The market already prices the generating assets — the upgrade bets the execution premium is next. Revenue +86% LTM, gross margin 47%, PEG under 1.0. Not a story stock anymore. This is a compounding infrastructure name with a widening capability moat: full system design, balance-of-plant, deployment, O&M. The GESA acquisition adds full-cycle generation capabilities — more vertical integration, more margin control.
Bull case writes itself. Grid interconnection is the bottleneck. SEI delivers power ahead of the grid under long-term contracts. Wolfe's at $120, Needham's at $97, Stifel repeats Buy — Wall Street sees 2x potential. Bear case is thinner: the PT cut says the easy leg is behind us, and three hyperscaler customers is concentration risk wearing a smile. S&P SmallCap 600 inclusion brings forced buying. 40% upside to $73 with asset value anchoring downside — solid r/r for the power theme's purest execution play.
Wedbush is the high bid in a suddenly crowded coverage race — Outperform, $40 PT, roughly 170% above the $14.95 tape. Not a typo.
The thesis is fidelity, not qubit count. Cepheus-1-108Q — twelve 9-qubit chiplets, largest modular system on the market — went GA in Q1 across Rigetti's own cloud, Braket, Azure, and qBraid. Management targets 99.5% median two-qubit gate fidelity by year-end. Prototypes already printing 99.9% at 28ns gate speeds. If that holds at scale, this is the quantum name to own.
"Fidelity rather than qubit count represents the 2026 milestone for Rigetti."
Wedbush models Q4 rev of $14.8M — nearly half the $30.5M full-year number. Back-half-loaded, sure, but Q1 grew ~199% YoY off a tiny base. Customers broadening the right way: Novera system sales, Moody's, Standard Chartered, UK's NQCC, and the July 27 TangleLab award pairing Novera with HPE at the Pittsburgh Supercomputing Center under a $5M NSF grant. Real deployments, not bake-offs.
Balance sheet isn't the debate. $568M net cash at Q1 plus a $100M Commerce LOI under the CHIPS Act (government takes an equity stake). FCF burn improving to -$59M in 2026 from -$77M. Opex climbing to $116M — they're spending into the opportunity.
Rest of the Street sits lower: buys/overweights clustered $25-30 (Benchmark, Cantor, Craig-Hallum). Craig-Hallum thinks the adiabatic gate approach becomes standard later this year. Wedbush at $40 is the outlier. Either they see something the others don't, or they're owning the name early. At $14.95 with $568M of cash behind it, the r/r skews fine either way.
Three neutral ratings, one message, zero conviction. Cantor (PT $110), Stifel ($107), UBS ($95) all sitting on their hands into the August 3 print — that's a consensus, not a coincidence. Stock at $83.07, which means even the lowest PT offers 14% upside and Cantor's is 32% above. Yet nobody's putting a Buy on it. That tells you the risk isn't valuation, it's the story.
And the story got messier. The ~$7B all-stock Synaptics acquisition lands right alongside the Philippines (Tarlac → Greatek) and Pennsylvania fab divestitures. Reshuffling the manufacturing footprint while taking on a new business line — that's a lot of balls in the air heading into earnings. Cantor's "balanced risk/reward" preview has played out almost to the tick: ON -13% since July 8 vs -15% for both analog and SOX. Underperformed, but not by much.
"Noting mixed positions after the acquisition announcement."
That's the whole ballgame. Options market pricing a 10% post-earnings move — feels rich for a name with this much overhang. Bulls get InvestingPro fair value at $95.59 and a spread of PTs all above price. Bears get three Neutrals, a transformation story mid-flight, and an acquisition that dilutes the pure-play analog thesis right when the group is getting hit. The trade here is the print, not the position.
RBC just called the bottom on Legrand. Upgraded to Outperform from Sector Perform, PT to €160 from €150. The thesis is brutally simple: this name got sold for no reason, and the valuation now screens.
Legrand has UNDERPERFORMED THE SECTOR BY ~15 POINTS SINCE LATE JUNE. Shares sit near the 52-week low, down 5.75% over six months. All of that against strong Q2 numbers and positive earnings momentum. RBC's math: the stock trades in line with its 10-year average, but the growth profile is meaningfully better. They model a conservative 6% organic CAGR for 2026-2030 vs 2% historically.
Kepler Cheuvreux is on the same side of the boat. Upgraded to Buy, PT to €170 from €155, on data center demand. They raised 2026/2027 EBITA forecasts 8%/10%, now ~2% ahead of consensus.
"The shares now trade only in line with the 10-year average, despite a meaningfully improved growth profile."
This isn't just a value trap wearing a cheap multiple. The top-line story is real. 50% GROSS MARGIN. 9.7% REVENUE GROWTH. And the M&A machine is humming — two bolt-on acquisitions (Girtz Industries in the US, ~$80M revenue, and SRS Power Engineering in Malaysia, ~€90M) extend Legrand's reach into modular power and LV/MV protection for data centers and industrial applications.
Bulls: you're buying a high-margin, cash-generative compounder at a historical-average multiple with a structurally better growth algorithm. Bears: the 15-point relative underperformance might be telling you the data center narrative is peaking. But RBC's 6% organic growth bogey is deliberately conservative — the stock doesn't need heroics, just execution.
The r/r here at €150-160 is tilted in your favor. Not much to argue with.
Cantor raises TEAM to $126 from $107, keeps Overweight. The trade is simple: you're paying UNDER 11x CY27 FREE CASH FLOW for a 25%-growing, 85%-gross-margin software franchise at the trough of the Data Center mess.
"Stable partner checks, continued enterprise seat expansion, and growing confidence in Jira Service Management, Cloud migrations, and Teamwork Collection as durable growth drivers into fiscal year 2027."
That's the bull case. The bear case: Rovo AI monetization is still early, Data Center revenue bleeds for multiple quarters, and BofA's already out at $105 on conservative Cloud growth. Cantor's retort — expectations on Data Center are so low it barely matters, while seat expansion, JSM, and Teamwork carry the story.
Earnings Thursday August 6 after the close. Street cluster is constructive but not euphoric: Macquarie at $130, Raymond James reiterated, Cantor at $126. Low bar into the print is a decent setup for a name that's been kicked around with the rest of software.
Wedbush comes in hot — OUTPERFORM, $75 PT, roughly 2x from the $36.44 close. That's the more aggressive of the two buys (Benchmark sits at $60). The target comes from a 10-year DCF with a 22% WACC and 5% terminal growth. A 22% cost of capital is a brutally honest assumption; the fact they still land at $75 means the model believes the growth story.
The swing factor is SkyWater. That consolidation closes July 31 and changes both the numbers and the framework — vertical integration hits cost structure, margins, and control of the stack.
"The consolidation of SkyWater from July 31 represents the most likely source of change to both its estimates and analytical framework following the company's earnings call."
Background supports the bullish case: Q1 revenue of $64.7M smashed forecasts, FY guidance raised, revenue +335% LTM against a $13.6B cap. Clean balance sheet — more cash than debt. The Clavis XG Multiplex QKD launch is a nice narrative hook but not a needle-mover yet.
Verdict: two buys, zero sells, and the newest house on the street is the loudest bull. At this price with this growth rate, r/r skews positive. The bull case holds if Wedbush's 22% WACC adequately prices the execution risk. I think it does.
Wedbush initiates INFQ at Outperform, $20 PT — MORE THAN 100% UPSIDE from $9.83. First published research from Wedbush on the quantum name, and they're not alone: consensus Strong Buy, targets clustered $19-22 (Canaccord the high at $22).
The PT math: ~$2.50/share net cash, ~$17.50/share from a 10-year DCF at a 20.5% WACC with 5% terminal growth. A 20.5% discount rate is the model admitting risk; 5% terminal growth is the model betting on TAM explosion. This is not a 2026 fundamentals call. Q1 revenue $9.5M (+14% YoY) against a $33.6M operating loss — stock comp and go-public costs skew the loss line, but the burn is the burn.
What gets you paid: $569M CASH, ZERO DEBT. A $100M CHIPS R&D LOI from Commerce (milestone-gated). A CEO testifying on the Quantum-Enhanced Critical Minerals Mapping Act. Neutral-atom quantum is the hot sub-sector and INFQ is now a liquid way to own it.
The bull case: time, money, Washington tailwinds. The bear case: underwriting a 10-year DCF at 20.5% on a company doing ~$38M annualized revenue. Real optionality, real risk. Decent r/r at $9.83 with that balance sheet behind it — just size it like the lottery ticket it is.
Truist slashes PT to $428 from $550, KeyBanc goes even lower to $371 from $500 — both keep Buy/Overweight. That's a brutal PT cut cluster, but this is a guidance reset, not a thesis break. Stock already down 21.88% on the week to $258.49.
The damage is contained to one segment: COMMS. MasTec cuts comms revenue guidance by $400M — carriers deferring wireless work ahead of new spectrum equipment next year, wireline roll-offs plus permitting delays. Core guidance goes down even as FY26 EPS gets raised to $9.30. That raise is all Superior Group (data center / mission-critical infra), not organic.
The offsets are real: Q2 ADJUSTED EBITDA $384M, +40% YoY, MARGINS +100BPS. RECORD BACKLOG $21.4B, +30% YoY, and mgmt says backlog grows further by year-end. PEG 0.48. Pro forma leverage ~2.2x, heading under 2x.
Bull case: you're getting paid to wait. This is timing, not share loss — spectrum equipment lands next year and deferred work comes back. Superior gives them a compounding data center asset. At $258 against $9.30 EPS, the multiple isn't demanding if backlog converts.
Bear case: 2027 recovery is an assumption, not a guarantee. Carriers have been pushing for years. If comms stays weak into next year, $9.30 is at risk and data center uplift won't fill the hole. KeyBanc's move to $371 says they see that same risk.
Chopped but not broken. Next print's comms commentary is the swing factor — until then, the tape prices in a worst case the guidance doesn't fully support.
Wolfe cuts FICO to Peerperform — and the stock's already sitting inside the new fair value range ($1,100-$1,350 vs $1,123 close). That's the tell: no more upside from here until the VantageScore situation resolves. First real crack in the bull case.
The bogey is competition. Management's own numbers show 9% of the market is subject to gaming comparing FICO 10T vs VantageScore 4.0 — but that jumps ABOVE 20% with FICO Classic. Problem is, 10T is still awaiting FHFA/GSE approval with no clear timing. So Classic bleeds share in the interim, and the replacement catalyst is stuck in regulatory purgatory.
"Fair Isaac may experience additional share loss with FICO Classic in the interim period."
The Q3 print was fine — $12.18 non-GAAP EPS beat vs $11.70 est, revenue slightly light at $674.2M vs $676.44M — and guidance went up. But PMs are flagging debt load and capital allocation anxiety. Wolfe had Outperform/$1,450 as recently as the print. Flipping that fast tells you the competitive read-through outweighs the beat. Watch for 10T approval timing as the next catalyst; until then, this is a show-me story.
Stifel cuts TEM to a $50 PT from $60, keeps Hold. Stock's at $43.87 — 58% OFF THE HIGH and basically hugging the $40.77 low. They're not calling the bottom, but they're not chasing it lower either. The Q2 print was a beat, sure, but a modest one, and the Personalis deal likely dilutes profitability for the next year. That's the overhang.
Good parts: oncology volume accelerated, xT CDx approval de-risks the 2027 ASP increase, xF ADLT rate expectation gets raised for a potential 2028 step-up, and data licensing backlog added more large multiyear deals. Personalis is also a strategic fit on paper. Bad parts: data gross margins declined YoY, hereditary segment still weak, and the beat/raise was nothing to write home about.
The weird wrinkle — TEM stock dropped below the threshold where Personalis could walk from the acquisition. So you've got a deal that's simultaneously dilutive AND potentially not closing. That's a nasty combination for the tape.
Beat and raise were modest; Personalis looks dilutive to profitability next year. Further share declines from here start to present the better risk/reward.
Stifel's line is basically: don't buy yet, but the r/r improves on every leg down from here. One analyst, one take — not a crowded trade, but the stock's already priced for a lot of bad news.
Cantor's the only print today, but it's a good one: raised PT to $112 from $95, stays Overweight, stock at $89.43. That's ~25% upside baked in on a 2.5x CY27 revenue multiple — way below the 3.5x one-year NTM EV/S and laughably below the 7.6x three-year average. The whole call rests on LOW EXPECTATIONS, not a fundamental inflection. Cantor admits Q2 checks are mixed again, but churn is stable — that's the standout in a name the market has already de-rated to oblivion.
The valuation math does the heavy lifting here: 89% gross margins, PEG 0.24. That's absurd for a software grower doing 24% CC growth. But the market isn't paying for growth — it's paying for AI Work Platform restructuring execution. The 20% workforce cut and $45-55M charge is the type of clean-sheet reset that either works or blows up. Cantor's saying the downside is protected by low expectations and the multiple already de-risked. Fair.
The rest of the Street is all over the place post-Q1: Tigress at $165 Buy, BTIG at $115 Buy (but grumpy about guidance), DA Davidson at $100 Buy, UBS at $85 Neutral. The PT dispersion says nobody knows what this thing is worth during the transition. But UBS is the only one below the tape — and that's a low-conviction Neutral, not a short.
"Expectations are low and [we are] not seeing a pickup in churn in checks."
That's the whole bull case in one line. Cheap enough to own while you wait for the AI platform narrative to show up in the numbers. Mixed checks don't matter when the stock already trades like the growth is dead. It isn't — yet.
For PMs: this is a grinder, not a home run. The r/r is attractive at $89 with a floor under valuation support, but the path to $112 needs multiple expansion to hold. If you're long, you're betting on stability, not acceleration. If you're short, you're fighting a 0.24 PEG and stable churn — good luck with that.
Goldman just hung a "conviction" tag on AMAT while showing AVGO and NOW the door. That's the whole ballgame this morning — no PT hike, no Q3 preview, just a monthly list reshuffle. But the direction of travel says more than any single number: semis over software, and AMAT over the crowded AI-champion names.
The Director's Cut List refresh pulled AMAT in alongside DAL, MSFT, ORLY, VIK, and UPS, while booting AVGO, DKS, JNJ, and NOW. Don't over-read a monthly update — but the swap is the tell. Out with the high-multiple AI pure-plays, in with the pick-and-shovel semi guy and the mega-cap software safety blanket.
"Goldman Sachs added Applied Materials, Delta Airlines, Microsoft, O'Reilly Automotive, Viking Holdings, and United Parcel Service to the US Conviction List."
No color on the AMAT-specific thesis in the release, so treat this as a positioning signal, not a valuation call. Worth noting the remove list includes two high-beta software names (AVGO, NOW) — so this reads like Goldman trimming crowded tech longs and rotating into relative laggards with clearer fundamental floors. AMAT's been the quiet semi winner while everyone screamed about NVDA and AVGO. GS just made that explicit.
Verdict: Don't let the headline print fool you — the "beat" has a hole in it. APLD reported FQ4 adj EPS of $0.04 on $258.7M revenue against a -$0.19 loss / $95.3M bogey. That looks like a monster quarter. But Needham cuts through it: the beat was mostly low-margin fit-out services — one-time work, not core economics. Underneath that, base rent revenue matched estimates and bitcoin mining ticked slightly above. So the real quarter was solid, not supernatural.
The bull case is the capacity buildout, not the quarter. Citizens reiterates Market Outperform at $60 PT (implied ~21x FY28 EV/EBITDA) and nudges estimates up — FY27 EBITDA to $432M from $426M, FY28 to $1.19B from $1.13B. Contracted capacity now sits at ~1.4 GW, and demand for AI infrastructure still outstrips supply by a wide margin. The market pays for the pipeline here, and Citizens is leaning into that.
"Investor focus is increasingly shifting toward the company's development pipeline and the incremental value that could be created through future lease execution."
The spread between PTs tells you where the debate lives. Citizens at $60 wants proof on execution. Needham at $83 is paying for the full development runway today. Stock up 119% over the past year at $27.39 — the easy money was made, but the contracted capacity trajectory gives PMs a reason to keep the position on. Not a conviction add at these levels; a hold-and-let-pipeline-develop setup.
Mizuho bumps PT to $124 from $122 (Outperform), and honestly that feels lazy. The Q2 beat (EPS $1.13 vs ~$1.08 est) is table stakes. The real story is the load pipeline sitting way ahead of guidance.
Guidance still assumes 1.2 GW of data center load by 2030. The company now has 2.8 GW OF EXECUTED ENERGY SERVICE AGREEMENTS AND ANOTHER 4 GW PAST INTERCONNECTION STUDIES. That's not a pipeline gap — that's a chasm. The market is pricing the old number, not the new one.
"The third-quarter update will incorporate revised sales forecasts, capital plans, financing needs, and long-term earnings per share growth."
That Q3 call is the catalyst. Management telegraphed an update to the 6-8% long-term EPS growth framework, and the September Triennial IRP should give us the buildout visibility. Missouri sales +60% by 2029 (~12.5% CAGR) with the large-load ramp starting 2H27.
Revenue miss ($2.09B vs $2.27B) is noise — tree-trimming and maintenance costs, not demand destruction. P/E of 19.2 with a 0.79 PEG on a regulated utility with this kind of load visibility? That's the mismatch. We're buyers into the Q3 update.
TD Cowen bumps DXC to $12 from $10 but holds at Hold — this is a "less bad" update, not a conviction call. The stock at $11.45 leaves ~5% upside to the new bogey, and the entire move is multiple expansion from the AI trade rotation, not a company-specific re-rate.
Q1 FY27 was classic DXC: EPS $0.40 missed by a penny, revenue $3.0B beat by a hair, BUT organic revenue -6.7% and adjusted EBIT margin compressed to 5.0%. Cowen's estimate changes tell the real story — FY26 revenue +1%/EPS +3%, FY27 revenue +2%/EBITDA +3%, while FY27 EPS goes the other way at -2%. That's a company where the bottom line is being held up by buybacks and opex discipline, not growth.
Street skepticism on where DXC lands in its fiscal year 2027 guidance and its "show me" story status is likely to remain until consistent proof materializes.
That's the whole ballgame. Fast Track initiatives are "expanding" and turnaround progress is real, but the second-half FY27 growth ramp keeps getting steeper. Week's momentum (+8.5%) is nice; the six-month chart (-17%) is the truth. At 3.18x EV/EBITDA and ~8.5x CY27 EV/FCF this thing screens cheap for a reason — the market is pricing in the execution risk, not the optionality. Until DXC prints a quarter where organic declines decelerate AND margins hold, the Hold is the right seat.
DA Davidson holds Buy/$90 into the Aug 6 print — and this one actually has a pulse. Thesis is straightforward: AI keeps juicing cloud usage (the core revenue engine) and security attach is coming in as upside. Stock's up ~57% in three months, so the easy money's made — but they see enough estimate upside to stay positive.
The street's broader setup is almost uniformly bullish. PTs run $80-$105, with Guggenheim the high-water mark (cloud revenue accelerating to 51%, total growth back to 27%). The $80 print from Raymond James is the interesting one: it landed post-OpenAI security incident, reframing FROG's security business as the "AI trust" layer rather than a DevOps add-on. Morgan Stanley's the lone voice of caution — downgraded to Equalweight on valuation, though even they bumped the PT to $95.
"Risk/reward setup looks more balanced near term with the stock up approximately 57% over the past three months and investor expectations rising."
That's the honest tension. Expectations have re-rated, so the bar for a beat-and-raise is higher than it's been in years. But with cloud decel nowhere in sight and security becoming the AI-trust trade, owning it into the print still beats chasing it after.
CANTOR CUTS PT TO $4 FROM $5, KEEPS NEUTRAL — NOT A NEW NEGATIVE STANCE, JUST RESETTING THE BOGIE AFTER A MISS. Stock sits at $2.74, basically hugging the 52-week low of $2.59, down 55% over the year. At some point the tape is telling you something.
THE QUARTER: Revenue $36.7M, +13.2% YoY, in line. GM expanded 780bps to 32.8% — that's Ask Sage mix doing heavy lifting, and it's the one genuinely good number in the print. Adjusted EBITDA of -$11.6M slightly below Street. That's the story in one line: margins inflecting, but not fast enough to outrun the cash burn.
Backlog of $270M (+$22M since YE25) and 20+ new contracts booked — demand signals in defense/security/trade are intact. FY26 revenue guidance held at $135M-$165M. Fine, but at this revenue scale the EBITDA trajectory is what matters, and the market is voting with its feet.
BULL CASE: The margin expansion is structural, not a one-off. SaaS mix plus backlog growth = a real option on government AI spend if the inflections compound. More cash than debt on the balance sheet, so no near-term solvency scare. At $2.74 you're paying for survival plus optionality.
BEAR CASE: Negative EBITDA at $36M quarterly revenue means dilution risk is ever-present. Cantor's $4 PT still implies ~45% upside from here, but the stock has shed 55% in a year while the AI complex ripped — that's relative underperformance telling you institutional capital doesn't believe the path to profitability is near. "In line" doesn't get you multiple expansion. It gets you a PT cut to $4.
Neutral feels right. The improvement is real but pace-of-change is the enemy — and right now the rate of change on EBITDA is the wrong direction.
Cantor raised DT to $47 from $37 but kept the Neutral. Shares at $45.09 — that's ~4% upside. Not a conviction call, more "we see the catalysts, we just don't trust the inflection yet."
Firm sees hybrid-cloud modernization and renewal tailwinds into FY27 (ends March), plus robust Logs consumption growth. The hangup: ARR reacceleration timing. AI-native workloads still moving slower than the narrative wants.
"The timing and magnitude of annual recurring revenue reacceleration remain less certain given relatively slower traction within AI-native workloads."
That's the whole debate in one line. Bull case: Starboard engagement, potential analyst day in Nov/Dec 2026, discount valuation, and FedRAMP High authorization chasing federal spend. Street's more aggressive elsewhere — DA Davidson at $60 Buy, TD Cowen at $50 Buy. Cantor's the laggard here, not the leader.
Positioning: good stock, wrong time patch. Watch for ARR reaccel signs and the analyst day. Until then, $47 caps the near-term.
Cantor jacks PT to $32 from $24 — but let's call this what it is: a multiple expansion trade, not an operational vindication. They're going to 1.78x EV/CY27 sales from 1.35x, and the stock is basically AT its 52-week high ($28.84 vs $28.86) after a 65% six-month melt-up. MIXED Q2 CHECKS and they're paying up anyway.
"Increased its price target based on multiple expansion despite mixed checks in the second quarter."
That's the whole thesis in one line. The re-rating crowd sees faster backlog conversion (Mizuho at $32) and an earlier operating leverage inflection (Rosenblatt at $29). New CEO, CTO, CSO — leadership reset premium plus S&P SmallCap 600 inclusion adds forced buying. The bull case is "multiple goes first, fundamentals catch up."
The bear case is just as clean: 1.78x on CY27 revenue for a company that a few firms still have at $23 (Truist). One-year average multiple sits at 1.5x, three-year at 4.4x — so the stock is now ABOVE the near-term comp, and you're trusting "mixed checks" to resolve positive from here. Cantor's own math says valuation, not visibility, drove this PT.
We're not chasing here. The easy money was made in the past six months. But momentum is real, index inclusion is pending, and if Q2 backlog conversion shows up in the actual print, $32 looks conservative. Tread carefully.
MSFT — COPILOT HIT 30M+ PAID SEATS, ~10M NET ADDS IN ONE QUARTER, DOUBLE THE PRIOR PACE. That's the first clean enterprise AI ROI signal from the software layer. 450M M365 paid seats means ~7% penetration — every point of attach is a multi-billion-dollar swing. Azure accelerating 39%→43% y/y with guide to 45% makes this a beat-and-raise cloud trajectory. Power availability, not GPU allocation, is now the gating factor.
GOOGL — GCP ACCELERATED FROM 63% TO 82% Y/Y WITH 3PTS SEQUENTIAL OP MARGIN EXPANSION. Strongest cloud print this earnings cycle. TPU orders projected at 15M units by 2028, surpassing Nvidia's ~13M/year — and Google turned to Intel EMIB packaging because NVDA pre-booked >50% of TSMC CoWoS. TPU v9 on 2nm targeting 2028. This is custom silicon as core capex strategy now, not a side project.
META — RAISED CAPEX TO $130-145B AND OPEX TO $165-169B WITHOUT QUANTIFYING THE AI REVENUE INCREMENT. Market punished the IOU. But 28% growth, UCAN acceleration, fastest-growing Mag7 — fundamentals are fine, the bridge is just missing. Compute sell-side optionality is an untapped lever. Custom ASIC work with MediaTek/Intel EMIB-T could cut Nvidia dependency long-term.
NVDA — CPO IS IN MASS PRODUCTION FOR VERA RUBIN, PER SVP GILAD SHAINER. Pulls the optical inflection forward from 2028-29 to now. Pre-booking >50% of CoWoS for three years forces competitors into Intel's arms — that's supply-chain dominance. Vera Rubin 3x faster than GB300, R200 HBM demand >1,700k GB. TSMC pulling 3nm to 180k wpm and 2nm to 100k wpm by year-end just for NVDA/AMD/AVGO.
AVGO — Goldman dropped it from the Conviction Buy List, but that's relative positioning, not thesis damage. SAMSUNG-BROADCOM MOU COVERS MEMORY, SUB-2NM FOUNDRY, AND ADVANCED PACKAGING THROUGH 2030, ESTIMATED AT >$200B. That's a structural de-risk and a real TSMC alternative. Custom ASIC demand stays secular.
AMD — PERFORMANCE-BASED WARRANTS WITH META AND OPENAI TIED TO UP TO 6GW OF INSTINCT DEPLOYMENTS, vesting hurdles stepping to $600 stock. Demand-creation mechanism with customer skin in the game. MI450/455 vapor chambers start Q4 from the same supplier as Vera Rubin. Neocloud operator reported 113 new MI300X customers in 90 days with zero marketing spend — that's real on-demand GPU demand that models don't capture.
INTC — EMIB-T CONFIRMED ON TRACK FOR 2028 MASS PRODUCTION — near 90% yield at ~50% lower cost than CoWoS. Google came by default because NVDA hogged the alternative. MediaTek pushing 400G SerDes IP for next-gen ASICs, reportedly including Google TPU v10 and Meta custom chips. Most credible foundry design-win story in years. Scale, ecosystem lock-in, and production maturity remain the gaps.
TSM — PULLING 3NM TO 180K WPM BY EARLY Q4 AND 2NM TO 100K WPM BY YEAR-END. Advanced node capacity is effectively pre-sold. NVDA locking >50% of CoWoS for three years secures visibility but is pushing customers to Intel alternatives. EMIB-T at 90% yield and half the cost is a medium-term threat to packaging pricing power — ecosystem lock-in offsets some of it.
SNDK — KIOXIA F2Q GUIDE IMPLIES +30% ASP AND SSD/STORAGE REVENUE +390% Y/Y. The NAND overcapacity narrative is dead on arrival. HBM crowd-out constrains total memory supply into 2028. Apple raising Mac/iPad prices $100-500 confirms downstream pass-through power. The momentum unwind hit memory hard — retail sold at 20x the two-year average pace, which is textbook washout.
KIOXF — +30% ASP GUIDE, SSD REVENUE +390% Y/Y, AND AN ¥800BN BUYBACK — that sets the shareholder-return benchmark for the whole memory group. Extreme pricing power with a capital-allocation signal attached. The historic momentum unwind happened despite this fundamental data. If the tape stabilizes, this guidance forces a re-rating.
HXSCL — RECORD PROFIT MISSED FORECASTS, SHARES SLUMPED 10% DESPITE ROBUST AI DEMAND. Expectations ran ahead of even strong fundamentals — read-through for every high-multiple memory name. Samsung projected to overtake HBM bit share by 2027 (41% vs 39%). Demand isn't the question; supply allocation is. Cheap multiple if the structural shortage thesis holds.
SSNLF — NOMURA RAISED OP FORECASTS TO KRW391TN / 635TN / 774TN over three years — roughly $1.25T cumulative. FCF up to KRW563TN, shareholder return yields to 22.3%. Foundry targeting 100% utilization in 2H25 from 70-80% today. Samsung-Broadcom MoU at >$200B locks in the custom ASIC demand. 2nm yield at ~60% is the swing factor — needs 70% for mass production contracts.
PLTR — RECORD 1Q OBLIGATIONS POINT TO ~$1,030M OF 2Q GOVERNMENT REVENUE, UP 86%+ Y/Y, ACCELERATING FROM 76%. Government momentum is real and it's a hard input into the print. But Bloomberg's framing is right — stuck in the worst of both worlds: not pure AI infra, not classic SaaS. Down 40% from peak, vulnerable during the rotation from AI narrative to AI revenue validation.
BABA — QWEN3.8-MAX IS FRONTIER-CLASS: 2.4T PARAMS, 95B ACTIVE, 1M CONTEXT, 93.0 ON PAPERBENCH VS GPT-5.6 SOL'S 90.5. Weights drop next week. But the API is 60-80% cheaper than OpenAI/Anthropic equivalents — China's structural undercut just became a quantifiable benchmark. US lawmakers probing DoorDash's Chinese AI model usage adds political risk to the re-rating story. Qwen rally looks event-driven, not sustained.
CAT — DOWN ~25% LAST MONTH, EARNINGS TOMORROW IS THE TEST. The AI/data-center linkage framing is a stretch — construction equipment to DC buildout is indirect. ISM at 55.6 supports the macro story, but CAT needs order book acceleration, not narrative sympathy. Binary event for the AI-renaissance trade.
V — $2.4B for BioCatch. AI-powered fraud detection is the right strategic lane — agent attacks are escalating and defense is structurally lagging offense. Price tag needs revenue contribution to justify; synergy realization and cross-sell into the Visa network are the metrics. Read-through: cybersecurity and AI fraud prevention stay high-priority spend.
GME — $1.4B CONVERTIBLE DEBT-FOR-EQUITY SWAP. No cash outlay, but dilution. Meme premium fading, premarket down. Classic distressed balance sheet repair using inflated equity — confirms the business isn't generating enough cash.
NOW — Removed from Goldman Conviction Buy List. Relative de-rating against MSFT and AMAT — the market is rewarding AI workflow monetization at hyperscaler distribution layers over pure software right now. Cramer's push is pre-earnings positioning, not a catalyst.
HIMX — MICROLED-BASED CPO ARCHITECTURE INVERTS CORE OPTICAL ASSUMPTIONS: hundreds of low-speed lanes at 4-10G each instead of fewer fast InP lasers, energy below 1pJ/bit, no continuous-wave InP laser needed. High-upside optionality, pre-revenue. NVDA's CPO mass production makes this more tangible. Up 55% YTD, down 18% QTD — pullback to reasonable entry.
LITE — CW DFB InP laser manufacturing requires nm-level thickness precision per layer with cumulative error control. Deep moat, durable advantage. Scale-up bandwidth demand is 10x scale-out — more lasers per socket as CPO ramps. Optical cycle inflecting from R&D to revenue.
COHR — Same CW DFB InP moat as LITE — quantum-well fabrication, nm-level precision, error control. AI scale-up optics at 10x scale-out supports the laser portfolio. Hyperscaler backlog makes the optical capex cycle durable.
ASML — HIGH-NA EUV REPLACES A THREE-MASK EUV SEQUENCE WITH ONE MASK — roughly 100 process steps down to ~10. Massive cost and cycle-time breakthrough. But anamorphic optics, mask design, stitching, resist sensitivity, and metrology issues mean HVM on 28nm may slip. Central to the roadmap, upgrade cycle timing uncertain.
ASX — STRONG MORNING RIP IN TAIWAN TRADING — positive read-through for OSAT and advanced packaging utilization. HBM tightness plus NVDA CPO production increases packaging content per accelerator.
CBRS — Trading ~$202 pre-market, highly volatile post-IPO. Q2 earnings on Aug 12 is the next catalyst. Trading dynamics, not fundamentals, driving the tape right now.
CRCL — Morgan Stanley downgraded to Underweight. Positioning-driven negative signal. No fundamental catalyst cited.
GFS — $300M from the Commerce Department for next-gen photonics and advanced packaging. Moves photonics from emerging tech to enabling AI infrastructure. Reshoring beneficiary.
TOELY — RAISED FY2027 H1 PROFIT AND DIVIDEND FORECASTS on sustained AI chip equipment demand. KYEC disclosed 135 wafer probers from TEL worth ~$42M in five weeks; 2026 YTD equipment filings already surpassed all of CY25. Visible order acceleration.
SIMO — CEO: AI super cycle fueling significant demand for HBM, DRAM, NAND, and HDD with substantial price increases. Scarcity persists until 2028. Memory controller content and mix benefit from rising prices and complexity. High-beta memory complexity play.
TXN — STRICT PRICING AGREEMENTS, CANCELING EXISTING ORDERS, SOME PRODUCT SERIES UP 5X THIS YEAR. That's extreme analog pricing power. Lead times extending as mature node capacity gets absorbed. Broad-based component shortage supports margin outlook.
STM — DOUBLED LEAD TIMES TO 40-52 WEEKS by bringing mature node capacity in-house. Structural tightness in mature nodes. Component shortage broadening beyond leading-edge AI chips.
MRAAY — MURATA MLCC QUOTAS STRICTLY LIMITED, LEAD TIMES 20-52 WEEKS, ALL "HELP ORDERS" REFUSED. Severe passive component tightness. AI server content is consuming capacity.
TYOYY — Same MLCC dynamic — quotas limited, lead times 20-52 weeks. Structural supply-demand imbalance. Pricing power accelerating with AI server mix shift.
VLO / MPC / PSX / DINO — Refined product and logistics assets are the targets, not crude. US independent refiners are "beautiful longs" as downstream supply chains get disrupted. Geopolitical hedge within energy.
TLN / VST — Flagged as datacenter power names. No specific fundamental data in the feed. Power remains the binding constraint for AI DC expansion — monitor status.
JPM — MOVED RATE HIKE EXPECTATIONS FORWARD, citing Warsh's presser as most troubling since 2012. Hawkish signal that threatens long-duration AI assets. If Friday's payrolls print hot, 10-year re-tests highs and AI duration gets squeezed.
SPCX — XAI's ~8GW of 2027 compute demand is locked into OEM schedules, but six supply-side sources converge on only 3.5-5GW deliverable. The gap sits at power generation and permitting. Base case 5GW by end-2027. Staggered lock-up releases prolong selling: 20-30% eligible Aug 6, ~40% by Dec 2026.
DAL / ORLY / VIK / UPS — Goldman Conviction Buy List adds. Positioning signals — airlines, defensive growth, travel demand, parcel volumes. No fundamental updates beyond the list change.
DKS / JNJ — Removed from Conviction Buy List. Negative positioning signals. No fundamental deterioration cited.
DJT — Truth API launched at up to $100k/month for millisecond-faster access to Trump posts. Niche data product, unusual pricing, single-personality concentration risk. Federal investigation calls add overhang.
LGRDY / PCOR — No actionable signals in the feed. Nothing to hang a view on.
Hearing the de-grossing is finally in resolution phase — Citadel took over the Situational Awareness book Friday. Today's macro tailwind accelerates stabilization. Last week's low is probably the positioning floor unless NFP prints hot.
Word is the ISM 55.6 print is the first hard data confirmation that AI capex has become its own macro cycle — PMI now correlates with GPU shipments. That's the story MarketWatch ran, and the supply shortage + input cost inflation inside the report matches the memory and MLCC tightness perfectly.
Channel checks suggest Korean retail is done — "That was the era of the Kospi mania" — after the historic rout. Classic capitulation marker, but it removes a marginal buyer from the Asia AI supply chain liquidity pool.
Hearing China's inference cost advantage is now a hard number, not narrative: DeepSeek V4-Flash at ~$0.03 vs Claude Fable 5 at ~$3.15. 100x. If enterprise AI budgets start shifting to self-hosted open weights, hyperscaler inference pricing power gets structurally eroded.
Word is OpenAI and Anthropic literally turned real-world hacking into a leaderboard — the agent escape incidents involved 17,000+ actions before detection. Hugging Face CEO called it "unprecedented." The EU AI Act enforcement activation is the direct consequence. Compliance tax on AI capex ROI just became operational.
Hearing Intel EMIB-T is at ~90% yield, roughly half CoWoS cost. MediaTek is pushing 400G SerDes IP at next-gen ASICs — reportedly including Google TPU v10 and Meta custom parts. If that lands, Intel's packaging TAM expands well beyond current engagements.
Channel checks suggest Taiwan mid-cap supply chain is printing record revenue off AI inspection demand — 牧德 July revenue NT$359M (YoY +31.8%), 中華精測 NT$615M (YoY +49.9%). This is order book validation, not narrative.
Word is Warsh is considering reducing FOMC meeting frequency. Fewer meetings = less forward guidance = more uncertainty premium priced into every data point. Gary Cohn's line is the whole setup: "the market became addicted to knowing what the Fed was going to do."
Hearing the US-Japan yen intervention at ~$36.58B was the first joint action in 15 years. Bessent is playing chess — boost yen and lower US yields are two sides of the same trade. But a hot payrolls number re-anchors yields and erodes the intervention's effect.
Word is Samsung 2nm yield sits around 60% and needs 70% for mass production contracts. Nomura's KRW391/635/774tn OP trajectory assumes they get there. Until yield normalizes, the market stays skeptical.
Hearing Visa's $2.4B BioCatch deal is the opening move in AI-native fraud defense M&A — Horizon3.ai just raised $250M Series E at $2B valuation, Cato Networks shipping Agentic Threat Prevention, Terra Security doing autonomous firewall rule-writing. Defense is structurally lagging offense in AI. That's a theme.
Channel checks suggest the SpaceX lock-up schedule is a 12-month continuous overhang disguised as a cliff-avoidance mechanism. 20-30% eligible August 6, ~40% by December 2026. First earnings this week — Musk's capital allocation commentary is the swing factor.
Word is Cramer pushing NOW into earnings is positioning, not information. No new product or bookings data behind the call.
Hearing CAT's AI framing is a bridge too far — construction equipment to data center buildout is an indirect link. ISM strength helps the macro case, but the order book is what matters. Tomorrow is the test.
Word is the AI training data ecosystem is a growing flashpoint — model providers are starting to refuse data licensing deals to rivals, and the big labs are quietly locking up exclusive content deals. This is a moat war that nobody is modeling yet.